[Effect of thymosin alpha 1 on cellular immune function in elderly patients with malignant tumor]. 2003

Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

To investigate the effect of thymosin alpha 1 on cellular immune function in the elderly patients with malignant tumor. Thirty patients with malignant tumor were injected with thymosin alpha 1 subcutaneously at the dose of 1.6 mg q.d. for the first month and q.o.d. for the following month. The number of T cell subgroups and the activity of NK cell in peripheral blood were detected and the quality of life of the patients were evaluated before treatment and at the end of treatment. Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. There were no side effects found. Thymosin alpha 1 can enhance the cellular immune function of the elderly patients with malignant tumor.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077596 Thymalfasin A thymus hormone polypeptide found in thymosin fraction 5 (a crude thymus gland extract) but now produced by synthesis. It is used alone or with interferon as an immunomodulator for the treatment of CHRONIC HEPATITIS B and HEPATITIS C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression, and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients. Thymosin alpha(1),Thymosin alpha1,Zadaxin,alpha1-Thymosin,alpha1 Thymosin
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013947 Thymosin Thymosin. A family of heat-stable, polypeptide hormones secreted by the thymus gland. Their biological activities include lymphocytopoiesis, restoration of immunological competence and enhancement of expression of T-cell characteristics and function. They have therapeutic potential in patients having primary or secondary immunodeficiency diseases, cancer or diseases related to aging. Thymosin Fs,Thymosins

Related Publications

Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
January 2016, Vitamins and hormones,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
January 1989, International journal of immunopharmacology,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
December 2023, International immunopharmacology,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
November 1992, Neuroendocrinology,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
January 1983, Journal of biological response modifiers,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
January 1982, Journal of immunology (Baltimore, Md. : 1950),
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
July 2018, Expert opinion on biological therapy,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
November 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
May 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Yun-mei Yang, and Xue-ying Lu, and Wei-dong Huang, and Mei-ya Shen
January 2004, International journal of immunopathology and pharmacology,
Copied contents to your clipboard!